$1.60 17.5%
ADTX Stock Price vs. AI Score
Data gathered: October 5

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Aditxt

None


Aditxt
Price $1.60
Target Price Sign up
Volume 44,320,000
Market Cap $260,000
Year Range $0.11 - $4.06
Dividend Yield 0%
Analyst Rating 0% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q2 '2444,00023,00021,000-7.5M-6M-4.189
Q1 '2480,00066,00014,000-15M-12M-36.820
Q4 '2381,000290,000-200,000-11M-8.2M-36.820
Q3 '23120,000110,00018,000-9.7M-8.1M-48.000
Q2 '23220,000190,00035,000-5.7M-4.2M-0.920

Insider Transactions View All

BNP PARIBAS SECURITIES CORP filed to sell 22,342 shares at $33.2.
September 7 '23
Albanna Amro A. filed to buy 1 shares at $20000.
July 21 '22

What is the Market Cap of Aditxt ?

The Market Cap of Aditxt is $260,000.

What is the current stock price of Aditxt ?

Currently, the price of one share of Aditxt stock is $1.60.

How can I analyze the ADTX stock price chart for investment decisions?

The ADTX stock price chart above provides a comprehensive visual representation of Aditxt 's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Aditxt shares. Our platform offers an up-to-date ADTX stock price chart, along with technical data analysis and alternative data insights.

Does ADTX offer dividends to its shareholders?

As of our latest update, Aditxt (ADTX) does not offer dividends to its shareholders. Investors interested in Aditxt should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Aditxt ?

Some of the similar stocks of Aditxt are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.